Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma act
Background: In Germany, patients with relapsed follicular non-Hodgkin’s lymphoma do not all receive the same treatment. In this study, 3 therapy regimens were analyzed which were considered to be simi
Described herein are chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In par
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations
These are peer-reviewed supplementary materials for the article ' Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
